GI Cell, Helixmith, and Catexcell Sign Joint Research Agreement on Cell Therapy
From the left, Hong Cheonpyo, CEO of GI Cell; Yoo Seungshin, CEO of Helixmith; Seo Jehee, CEO of Catexcell.
View original image[Asia Economy Reporter Lee Gwan-joo] GI Cell announced on the 28th that it has signed a Memorandum of Understanding (MOU) for collaboration on the development of innovative cell therapies based on the Immune Cell Expander Platform with Helixmith and Catexcell.
Through this agreement, GI Cell will conduct joint research on genetic materials necessary for cell therapy development with Helixmith and Catexcell, and plans to expand cooperation through separate contract manufacturing agreements for additional genetic materials required in the future.
Hong Cheon-pyo, CEO of GI Cell, stated, "With Helixmith and Catexcell, who possess leading technology, extensive R&D experience, and expert personnel in gene therapy development, we will strive to achieve innovative results in the field of cell therapy."
Hot Picks Today
At President Lee's Call to "Give Enough to Shock," Whistleblower Rewards Become a Real Lottery
- If They Fail Next Year, Bonus Drops to 97 Million Won... A Closer Look at Samsung Electronics DS Division’s 600M vs 460M vs 160M Performance Bonuses
- Lived as Family for Over 30 Years... Daughter-in-Law Cast Aside After Husband's Death
- Opening a Bank Account in Korea Is Too Difficult..."Over 150,000 Won in Notarization Fees Just for a Child's Account and Debit Card" [Foreigner K-Finance Status]②
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
GI Cell is developing allogenic NK cell therapies and patient-customized regulatory T cell therapies based on its own platform. Among these, the clinical trial application for the allogenic NK cell therapy is scheduled to be submitted in the second half of this year.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
